Remove Biosimilars Remove Communication Remove Medication Therapy Management (MTM)
article thumbnail

CMS Issues Sweeping End-Of Year Rule on Medicare Advantage and Medicare Part D

Putting Patients First Blog

Biosimilars and Generics The formulary inclusion of biosimilars and generics is essential in reducing the costs of medications for Medicare recipients. To enable lower cost medications, CMS would require that plan formularies prioritize access to biosimilars, generics, and affordable other alternatives.

article thumbnail

NHC Submits Comments to CMS RE CY 2026 Policy & Technical Changes to MA and Part D Proposed Rule

Putting Patients First Blog

This includes clear communication about how AI tools are used in clinical and administrative Transparency fosters trust and empowers patients and providers to actively participate in care decisions. Comprehensive Transparency: AI applications should be fully disclosed, explainable, and accessible to patients and providers in layperson terms.